bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue...

Published on 14 Nov 2024 on GuruFocus.com · via Yahoo Finance

Total Revenue: $10.6 million in Q3, down from $16.1 million in Q2. Projected Q4 Revenue: At least...

Read the rest of the article

Start tracking your investments with Statfolio

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article,...

Insider Monkey · via Yahoo Finance 29 Dec 2024

Traders purchased 27,165 call options on the company. This is an increase of approximately 1,278%...

ETF DAILY NEWS 6 Dec 2024

Shares of Verint Systems Inc. VRNT rose sharply in today's pre-market trading after the company r...

Benzinga 5 Dec 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69%

Investing.com 4 Dec 2024

Total Revenue: $10.6 million in Q3, down from $16.1 million in Q2. Projected Q4 Revenue: At least...

GuruFocus.com · via Yahoo Finance 14 Nov 2024

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge...

Insider Monkey · via Yahoo Finance 31 Oct 2024

bluebird bio BLUE registered revenues of $18.6 million in the first quarter, up from $2.4 million...

Zacks via Yahoo Finance 10 May 2024

bluebird bio, Inc. (NASDAQ:BLUE) Q1 2024 Earnings Call Transcript May 9, 2024 bluebird bio, Inc. ...

Insider Monkey via Yahoo Finance 10 May 2024

Bluebird bio Inc. (BLUE) has announced its first-quarter 2024 financial results, highlighting the...

Investing.com 10 May 2024

This development marks a major step in making the treatment accessible to patients with a history...

Investing.com 7 May 2024